drugset

drugset / Trial / NCT06971900

GATEWAY: A Phase 2a Study of PORT-77 in Adults With Erythropoietic Protoporphyria

NCT06971900 ↗

Phase 2 Enrolling by invitation 14 enrolled Portal Therapeutics, Inc. Celerion · collab

RandomizedCrossoverDouble-blindTreatment

Summary

A Phase 2a study of PORT-77 in adults with erythropoietic protoporphyria (EPP)

Timeline

Start: 2025-04-04
Primary completion: 2026-01-01
Completion: 2026-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PORT-77	Unknown	—	Oral

Indications